Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Functional and genomic characterisation of a xenograft model system for the study of metastasis in triple-negative breast cancer.

Johnstone CN, Pattison AD, Gorringe KL, Harrison PF, Powell DR, Lock P, Baloyan D, Ernst M, Stewart AG, Beilharz TH, Anderson RL.

Dis Model Mech. 2018 May 29;11(5). pii: dmm032250. doi: 10.1242/dmm.032250.

3.

Human breast adipose tissue: characterization of factors that change during tumor progression in human breast cancer.

Fletcher SJ, Sacca PA, Pistone-Creydt M, Coló FA, Serra MF, Santino FE, Sasso CV, Lopez-Fontana CM, Carón RW, Calvo JC, Pistone-Creydt V.

J Exp Clin Cancer Res. 2017 Feb 7;36(1):26. doi: 10.1186/s13046-017-0494-4.

4.

Stroma-derived but not tumor ADAMTS1 is a main driver of tumor growth and metastasis.

Fernández-Rodríguez R, Rodríguez-Baena FJ, Martino-Echarri E, Peris-Torres C, Del Carmen Plaza-Calonge M, Rodríguez-Manzaneque JC.

Oncotarget. 2016 Jun 7;7(23):34507-19. doi: 10.18632/oncotarget.8922.

5.

Metalloproteinase-dependent and -independent processes contribute to inhibition of breast cancer cell migration, angiogenesis and liver metastasis by a disintegrin and metalloproteinase with thrombospondin motifs-15.

Kelwick R, Wagstaff L, Decock J, Roghi C, Cooley LS, Robinson SD, Arnold H, Gavrilović J, Jaworski DM, Yamamoto K, Nagase H, Seubert B, Krüger A, Edwards DR.

Int J Cancer. 2015 Feb 15;136(4):E14-26. doi: 10.1002/ijc.29129. Epub 2014 Aug 18.

6.

The E2F transcription factors regulate tumor development and metastasis in a mouse model of metastatic breast cancer.

Hollern DP, Honeysett J, Cardiff RD, Andrechek ER.

Mol Cell Biol. 2014 Sep;34(17):3229-43. doi: 10.1128/MCB.00737-14. Epub 2014 Jun 16.

7.

Novel methylation biomarker panel for the early detection of pancreatic cancer.

Yi JM, Guzzetta AA, Bailey VJ, Downing SR, Van Neste L, Chiappinelli KB, Keeley BP, Stark A, Herrera A, Wolfgang C, Pappou EP, Iacobuzio-Donahue CA, Goggins MG, Herman JG, Wang TH, Baylin SB, Ahuja N.

Clin Cancer Res. 2013 Dec 1;19(23):6544-6555. doi: 10.1158/1078-0432.CCR-12-3224. Epub 2013 Oct 2.

8.

Tumor growth inhibitory effect of ADAMTS1 is accompanied by the inhibition of tumor angiogenesis.

Obika M, Ogawa H, Takahashi K, Li J, Hatipoglu OF, Cilek MZ, Miyoshi T, Inagaki J, Ohtsuki T, Kusachi S, Ninomiya Y, Hirohata S.

Cancer Sci. 2012 Oct;103(10):1889-97. doi: 10.1111/j.1349-7006.2012.02381.x. Epub 2012 Aug 29.

9.

Inhibition of tumor growth by antibody to ADAMTS1 in mouse xenografts of breast cancer.

Hirano T, Hirose K, Sakurai K, Makishima M, Sasaki K, Amano S.

Anticancer Res. 2011 Nov;31(11):3839-42.

PMID:
22110207
10.

The ADAMTS1 protease gene is required for mammary tumor growth and metastasis.

Ricciardelli C, Frewin KM, Tan Ide A, Williams ED, Opeskin K, Pritchard MA, Ingman WV, Russell DL.

Am J Pathol. 2011 Dec;179(6):3075-85. doi: 10.1016/j.ajpath.2011.08.021. Epub 2011 Oct 12.

11.

Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome.

Reynolds LE, Watson AR, Baker M, Jones TA, D'Amico G, Robinson SD, Joffre C, Garrido-Urbani S, Rodriguez-Manzaneque JC, Martino-Echarri E, Aurrand-Lions M, Sheer D, Dagna-Bricarelli F, Nizetic D, McCabe CJ, Turnell AS, Kermorgant S, Imhof BA, Adams R, Fisher EM, Tybulewicz VL, Hart IR, Hodivala-Dilke KM.

Nature. 2010 Jun 10;465(7299):813-7. doi: 10.1038/nature09106. Erratum in: Nature. 2010 Jul 15;466(7304):398.

12.

Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma.

Stokes A, Joutsa J, Ala-Aho R, Pitchers M, Pennington CJ, Martin C, Premachandra DJ, Okada Y, Peltonen J, Grénman R, James HA, Edwards DR, Kähäri VM.

Clin Cancer Res. 2010 Apr 1;16(7):2022-35. doi: 10.1158/1078-0432.CCR-09-2525. Epub 2010 Mar 21.

13.

Variable inhibition of thrombospondin 1 against liver and lung metastases through differential activation of metalloproteinase ADAMTS1.

Lee YJ, Koch M, Karl D, Torres-Collado AX, Fernando NT, Rothrock C, Kuruppu D, Ryeom S, Iruela-Arispe ML, Yoon SS.

Cancer Res. 2010 Feb 1;70(3):948-56. doi: 10.1158/0008-5472.CAN-09-3094. Epub 2010 Jan 26.

14.

Caveolin-1 (P132L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem cell/metastasis-associated gene signature.

Bonuccelli G, Casimiro MC, Sotgia F, Wang C, Liu M, Katiyar S, Zhou J, Dew E, Capozza F, Daumer KM, Minetti C, Milliman JN, Alpy F, Rio MC, Tomasetto C, Mercier I, Flomenberg N, Frank PG, Pestell RG, Lisanti MP.

Am J Pathol. 2009 May;174(5):1650-62. doi: 10.2353/ajpath.2009.080648.

15.

Altered expression of genes regulating angiogenesis in experimental androgen-independent prostate cancer.

Gustavsson H, Jennbacken K, Welén K, Damber JE.

Prostate. 2008 Feb 1;68(2):161-70.

PMID:
18076023
16.
17.

The carboxyl-terminal half region of ADAMTS-1 suppresses both tumorigenicity and experimental tumor metastatic potential.

Kuno K, Bannai K, Hakozaki M, Matsushima K, Hirose K.

Biochem Biophys Res Commun. 2004 Jul 9;319(4):1327-33.

PMID:
15194513
18.

ADAMTS1: a matrix metalloprotease with angioinhibitory properties.

Iruela-Arispe ML, Carpizo D, Luque A.

Ann N Y Acad Sci. 2003 May;995:183-90. Review.

PMID:
12814950
19.

ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165.

Luque A, Carpizo DR, Iruela-Arispe ML.

J Biol Chem. 2003 Jun 27;278(26):23656-65. Epub 2003 Apr 25.

20.

Expression of METH-1 and METH-2 in pancreatic cancer.

Masui T, Hosotani R, Tsuji S, Miyamoto Y, Yasuda S, Ida J, Nakajima S, Kawaguchi M, Kobayashi H, Koizumi M, Toyoda E, Tulachan S, Arii S, Doi R, Imamura M.

Clin Cancer Res. 2001 Nov;7(11):3437-43.

Supplemental Content

Loading ...
Support Center